ExploreWatchlistsPricing
  1. JP-listed companies
  2. Renascience Inc.
  3. Financials
  4. EBITDA

Renascience Inc. (4889)

Market cap
¥18.4B
P/E ratio
-53.3x
Rena Science develops pharmaceuticals, medical devices, and AI-powered software to address critical health challenges including cancer, diabetes, and age-related diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 2025-179-28.64%
Mar 31, 2024-250-24.66%
Mar 31, 2023-332+60.03%
Mar 31, 2022-208+149.55%
Mar 31, 2021-83-53.77%
Mar 31, 2020-180

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat